Loading organizations...
§ Private Profile · San Carlos, CA, USA
Range Biotechnologies is a technology company.
Range Biotechnologies provides a specialized platform focused on translational proteomics, which involves the validation and scalable deployment of protein-based diagnostic technologies. This approach enables the accurate quantification of multiple proteins across numerous samples, facilitating the practical application of proteomic discoveries from research into clinical use. The company develops precise molecular measurement tools designed to bridge the gap between initial protein identification and widespread clinical translation.
The company was co-founded by Brandon Wilson, Ph.D., Nicolo Maganzini, Ph.D., and Professor Tom Soh, who initially collaborated while Dr. Wilson pursued his Ph.D. in Chemical Engineering at Stanford University. Their collective insight stemmed from the understanding that their advanced technologies for quantifying human physiology required an entrepreneurial path to reach the individuals they were intended to benefit. They recognized a critical need for continuous, personalized physiological monitoring, moving beyond population-based diagnostics.
Range Biotechnologies serves patients and biotech companies by making advanced proteomic insights accessible for health screening, disease prevention, and individualized therapeutic strategies. The company's vision is to lead in translational proteomics, establishing a new paradigm in healthcare where protein data is as readily available and impactful as genomic information, leading to a more complete understanding of human health.
Range Biotechnologies has raised $5.0M across 1 funding round.
Range Biotechnologies has raised $5.0M in total across 1 funding round.
Range Biotechnologies is a biotechnology company founded in 2022, developing tools for translational proteomics to enable personalized health by precisely measuring proteins and unlocking comprehensive views of human physiology.[1][2][4][5] It serves researchers, healthcare providers, and patients aiming to advance health screening, disease prevention, and tailored treatments, addressing the gap between academic proteomics research and real-world clinical applications.[1][2][4] The company has raised $5.2 million in funding, operates from San Carlos, CA (with some sources listing San Francisco), and employs fewer than 25 people, showing early momentum through recognitions like being named an Innovation AveNEW company at SLAS 2025.[3][4]
Range Biotechnologies was established in 2022 by co-founders Brandon Wilson, Ph.D. (CEO), Nicolo Maganzini, Ph.D. (CTO), and Professor Tom Soh, who met while Wilson pursued a PhD in Chemical Engineering at Stanford University.[1][2] With over eight years of collaboration, the team—spanning expertise in molecular biology, chemistry, computer science, material science, and electrical engineering—realized their novel technologies for quantifying human physiology would stay confined to academia without entrepreneurship.[2] This interdisciplinary drive led to the company's formation, fueled by a mission to translate proteomics innovations into accessible tools for broader health impact.[2][4]
Range Biotechnologies rides the proteomics revolution, shifting from genomics to proteins—the functional drivers of biology—for next-generation health advancements like precision medicine and early disease detection.[2][4] Timing aligns with surging demand for personalized health amid post-genomic era limitations, where protein-level insights reveal dynamic physiology genomics misses; market forces include falling sequencing costs paralleling proteomics scalability and rising investments in biotech tools.[2][5] By democratizing proteomics, Range influences the ecosystem, empowering startups and labs to accelerate drug discovery, diagnostics, and preventive care, much like how sequencing firms transformed genomics.[1][4]
Range Biotechnologies is poised to lead translational proteomics, with $5.2M funding fueling product development toward accessible, genomics-rivaling tools for health screening and personalization.[2][3] Upcoming trends like AI-driven protein analysis and multimodal omics will amplify their trajectory, potentially expanding influence through partnerships and clinical validations. As they evolve from stealth to market leader, Range could redefine personalized health, fulfilling their origin promise of bringing Stanford innovations to patients.
Range Biotechnologies has raised $5.0M in total across 1 funding round.
Range Biotechnologies's investors include Artis Ventures (AV), Cota Capital, Civilization Ventures, Four Cities Capital, Hawktail, Page One Ventures, Pear VC, Tony Kulesa, Pillar VC.
Range Biotechnologies has raised $5.0M across 1 funding round. Most recently, it raised $5.0M Seed in June 2023.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jun 1, 2023 | $5M Seed | — | ARTIS Ventures, Cota Capital, Civilization Ventures, Four Cities Capital, Hawktail, Page ONE Ventures, Pear VC, Tony Kulesa, Pillar VC | Announced |